We are live on ! Find out more
VTAE

VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE

Delisted

VTAE was delisted on the 24th of October, 2016.

52 hedge funds and large institutions have $138M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2015 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 5

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

53% more funds holding

Funds holding: 3452 (+18)

14% more capital invested

Capital invested by funds: $120M → $138M (+$17.4M)

Holders
52
Holders Change
+18
Holders Change %
+52.94%
% of All Funds
1.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
28
Increased
16
Reduced
5
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
EC
51
EcoR1 Capital
California
-$3.44M -207,000 Closed
EI
52
EAM Investors
California
-$1.31M -78,477 Closed
ARTA
53
A.R.T. Advisors
New York
-$684K -41,150 Closed
Citadel Advisors
54
Citadel Advisors
Florida
-$451K -27,089 Closed
Susquehanna International Group
55
Susquehanna International Group
Pennsylvania
-$344K -20,687 Closed
BIM
56
Bogle Investment Management
Massachusetts
-$237K -14,285 Closed
VKH
57
Virtu KCG Holdings
New York
-$188K -11,295 Closed
TRCT
58
Tower Research Capital (TRC)
New York
-$50K -2,992 Closed
UBS Group
59
UBS Group
Switzerland
-$9K -566 Closed
Deutsche Bank
60
Deutsche Bank
Germany
-$13 -1 -50%
Bank of America
61
Bank of America
North Carolina
+$229 +17 New

VTAE Hedge Fund Activity: Q1 2015 in Review

52 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q1 2015, worth a combined $138M — up 14% from $120M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VTAE positions and 10 closed out — a net gain of 18 holders — while 16 added to existing stakes and 5 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $15.9M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.44M sold.

  • 52 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q1 2015, up from 34 in Q4 2014.
  • Funds reported $138M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q1 2015, up 14% quarter-over-quarter.
  • 28 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q1 2015 and 10 closed out, a net change of +18 holders.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q1 2015 was Fidelity Investments, an estimated $15.9M added.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q1 2015 was EcoR1 Capital, an estimated $3.44M sold.

Based on aggregated 13F filings for Q1 2015.